The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study

Home > Business

By Hardik in Business

Updated 3 years ago

ABIOMED, Inc. (NASDAQ:ABMD) AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Aclaris Therapeutics Inc (NASDAQ:ACRS) ( reacted to a positive mid-stage readout) Adaptive Biotechnologies Corp (NASDAQ:ADPT) Akari Therapeutics PLC (NASDAQ:AKTX) Aldeyra Therapeutics Inc (NASDAQ:ALDX) Alkermes Plc (NASDAQ:ALKS) Apyx Medical Corp (NASDAQ:APYX) Arvinas Inc (NASDAQ:ARVN) Beigene Ltd (NASDAQ:BGNE) Bicycle Therapeutics PLC (NASDAQ:BCYC) BIO-TECHNE Corp (NASDAQ:TECH)

#news #latest the-daily-biotech-pulse-fda-greenlights-mercks-heart-failure-drug-histogen-hit-with-clinical-hold-aptorum-gets-nod-for-commencing-human-study

the-daily-biotech-pulse-fda-greenlights-mercks-heart-failure-drug-histogen-hit-with-clinical-hold-aptorum-gets-nod-for-commencing-human-study

The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study

Related Posts